Addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
milk	O
fat	O
globule	O
membrane	O
to	O
ahigh	O
-	O
saturated	O
fat	O
meal	O
reduces	O
the	O
postprandial	O
insulinaemic	O
and	O
inflammatory	O
response	O
in	O
overweight	O
and	O
obese	O
adults	O

Meals	O
high	O
in	O
SFA	O
,	O
particularly	O
palmitate	O
,	O
are	O
associated	O
with	O
postprandial	O
inflammation	O
and	O
insulin	B-GP
resistance	O
.	O

Milk	O
fat	O
globule	O
membrane	O
(	O
MFGM	O
)	O
has	O
anti	O
-	O
inflammatory	O
properties	O
that	O
may	O
attenuate	O
the	O
negative	O
effects	O
of	O
SFA	O
-	O
rich	O
meals	O
.	O

Our	O
objective	O
was	O
to	O
examine	O
the	O
postprandial	O
metabolic	O
and	O
inflammatory	O
response	O
to	O
a	O
high	O
-	O
fat	O
meal	O
composed	O
of	O
palm	O
oil	O
(	O
PO	O
)	O
compared	O
with	O
PO	O
with	O
an	O
added	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
(	O
PO	O
+	O
MFGM	O
)	O
in	O
overweight	O
and	O
obese	O
men	B-OG
and	O
women	B-OG
(	O
n	O
36	O
)	O
in	O
a	O
randomised	O
,	O
double	O
-	O
blinded	O
,	O
cross	O
-	O
over	O
trial	O
.	O

Participants	O
consumed	O
two	O
isoenergetic	O
high	O
-	O
fat	O
meals	O
composed	O
of	O
a	O
smoothie	O
enriched	O
with	O
PO	O
with	O
v	O
.	O
without	O
a	O
cream	O
-	O
derived	O
complex	O
milk	O
lipid	O
fraction	O
(	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
)	O
separated	O
by	O
a	O
washout	O
of	O
1	O
–	O
2	O
weeks	O
.	O

Serum	O
cytokines	B-GP
,	O
adhesion	B-GP
molecules	I-GP
,	O
cortisol	O
and	O
markers	O
of	O
inflammation	O
were	O
measured	O
at	O
fasting	O
,	O
and	O
at	O
1	O
,	O
3	O
and	O
6	O
h	O
postprandially	O
.	O

Glucose	O
,	O
insulin	B-GP
and	O
lipid	O
profiles	O
were	O
analysed	O
in	O
plasma	O
.	O

Consumption	O
of	O
the	O
PO	O
+	O
MFGM	O
v	O
.	O

PO	O
meal	O
resulted	O
in	O
lower	O
total	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
021	O
),	O
LDL	O
-	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
046	O
),	O
soluble	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
(	O
P	O
=	O
0	O
·	O
005	O
)	O
and	O
insulin	B-GP
(	O
P	O
=	O
0	O
·	O
005	O
)	O
incremental	O
AUC	O
,	O
and	O
increased	O
IL	B-GP
-	I-GP
10	I-GP
(	O
P	O
=	O
0	O
·	O
013	O
).	O

Individuals	O
with	O
high	O
baseline	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
(	O
CRP	B-GP
)	O
concentrations	O
(≥	O
3	O
mg	O
/	O
l	O
,	O
n	O
17	O
)	O
had	O
higher	O
(	O
P	O
=	O
0	O
·	O
030	O
)	O
insulin	B-GP
at	O
1	O
h	O
after	O
the	O
PO	O
meal	O
than	O
individuals	O
with	O
CRP	B-GP
concentrations	O
<	O
3	O
mg	O
/	O
l	O
(	O
n	O
19	O
).	O

The	O
addition	O
of	O
MFGM	O
attenuated	O
this	O
difference	O
between	O
CRP	B-GP
groups	O
.	O

The	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
attenuated	O
the	O
negative	O
effects	O
of	O
a	O
high	O
-	O
SFA	O
meal	O
by	O
reducing	O
postprandial	O
cholesterol	O
,	O
inflammatory	O
markers	O
and	O
insulin	B-GP
response	O
in	O
overweight	O
and	O
obese	O
individuals	O
,	O
particularly	O
in	O
those	O
with	O
elevated	O
CRP	B-GP
.	O

The	O
postprandial	O
state	O
has	O
been	O
highlighted	O
as	O
an	O
important	O
transitory	O
period	O
when	O
significant	O
vascular	O
damage	O
can	O
occur	O
and	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
causal	O
processes	O
of	O
CVD	B-DS
(	O
1	O
).	O

Postprandial	O
inflammatory	O
and	O
lipaemic	O
responses	O
are	O
pronounced	O
in	O
individuals	O
with	O
obesity	B-DS
,	O
the	O
metabolic	B-DS
syndrome	I-DS
(	O
MetS	B-DS
)	O
and	O
type	B-DS
2	I-DS
diabetes	I-DS
(	O
2	O
–	O
5	O
),	O
in	O
part	O
because	O
the	O
magnitude	O
of	O
the	O
postprandial	O
inflammatory	O
response	O
is	O
correlated	O
with	O
insulin	B-GP
resistance	O
(	O
6	O
,	O
7	O
).	O

Current	O
literature	O
suggests	O
that	O
the	O
inflammation	O
of	O
the	O
postprandial	O
state	O
adds	O
to	O
the	O
already	O
pro	O
-	O
inflammatory	O
environment	O
in	O
individuals	O
with	O
obesity	B-DS
-	O
induced	O
metabolic	B-DS
disease	I-DS
,	O
intensifying	O
the	O
overall	O
systemic	O
inflammation	O
that	O
underlies	O
metabolic	O
dysfunction	O
(	O
8	O
).	O

Given	O
the	O
rise	O
in	O
overweight	O
and	O
obesity	B-DS
worldwide	O
(	O
9	O
),	O
potential	O
nutritional	O
interventions	O
that	O
can	O
limit	O
the	O
postprandial	O
inflammatory	O
response	O
would	O
be	O
of	O
great	O
public	O
health	O
benefit	O
.	O

The	O
postprandial	O
inflammatory	O
response	O
is	O
influenced	O
by	O
the	O
fat	O
content	O
and	O
composition	O
of	O
the	O
test	O
meal	O
(	O
10	O
–	O
13	O
).	O

It	O
has	O
been	O
shown	O
that	O
SFA	O
induce	O
inflammation	O
postprandially	O
(	O
8	O
).	O

Palmitic	O
acid	O
in	O
particular	O
appears	O
to	O
be	O
detrimental	O
.	O

The	O
consumption	O
of	O
palmitic	O
acid	O
acutely	O
increases	O
the	O
insulin	B-GP
response	O
compared	O
with	O
oleic	O
acid	O
and	O
n	O
-	O
3	O
fatty	O
acids	O
(	O
14	O
)	O
and	O
this	O
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
adverse	O
effects	O
of	O
palmitate	O
on	O
both	O
β	O
-	O
cell	O
function	O
and	O
insulin	B-GP
sensitivity	O
in	O
the	O
postprandial	O
state	O
(	O
15	O
).	O

Palmitate	O
,	O
either	O
as	O
an	O
isolated	O
fatty	O
acid	O
or	O
as	O
part	O
of	O
a	O
high	O
-	O
SFA	O
meal	O
,	O
increases	O
inflammatory	O
markers	O
in	O
the	O
postprandial	O
state	O
(	O
16	O
).	O

Palm	O
oil	O
(	O
PO	O
)	O
is	O
enriched	O
in	O
palmitate	O
and	O
has	O
been	O
used	O
widely	O
in	O
the	O
food	O
industry	O
as	O
a	O
substitute	O
for	O
trans	O
-	O
fatty	O
acids	O
,	O
which	O
are	O
known	O
to	O
have	O
deleterious	O
effects	O
on	O
CVD	B-DS
risk	O
(	O
17	O
).	O

Milk	O
fat	O
globule	O
membrane	O
(	O
MFGM	O
)	O
fractions	O
have	O
previously	O
been	O
reported	O
to	O
reduce	O
inflammation	O
in	O
in	O
vitro	O
and	O
animal	B-OG
models	O
(	O
18	O
–	O
21	O
).	O

MFGM	O
,	O
a	O
protein	O
–	O
lipid	O
complex	O
originating	O
from	O
the	O
apical	O
surface	O
of	O
mammary	O
epithelial	O
cells	O
,	O
surrounds	O
the	O
fat	O
globules	O
in	O
milk	O
and	O
is	O
found	O
in	O
dairy	O
products	O
at	O
varying	O
levels	O
.	O

Specific	O
proteins	O
and	O
lipids	O
of	O
MFGM	O
are	O
associated	O
with	O
health	O
-	O
promoting	O
bioactive	O
functions	O
.	O

For	O
example	O
,	O
one	O
major	O
MFGM	O
-	O
associated	O
protein	O
,	O
lactadherin	B-GP
,	O
was	O
reported	O
to	O
bind	O
and	O
neutralise	O
viruses	B-OG
,	O
reduce	O
intestinal	O
inflammation	O
,	O
improve	O
intestinal	O
permeability	O
,	O
and	O
repair	O
intestinal	O
epithelium	O
(	O
20	O
,	O
22	O
–	O
24	O
).	O

MFGM	O
-	O
derived	O
polar	O
lipids	O
were	O
reported	O
to	O
have	O
bactericidal	O
properties	O
,	O
bind	O
enterotoxigenic	O
pathogens	O
and	O
reduce	O
intestinal	O
inflammation	O
(	O
19	O
,	O
23	O
,	O
25	O
–	O
27	O
).	O

In	O
addition	O
to	O
functions	O
attributed	O
to	O
its	O
individual	O
components	O
,	O
MFGM	O
as	O
a	O
complex	O
also	O
reduced	O
inflammation	O
in	O
vitro	O
,	O
in	O
animals	B-OG
and	O
clinically	O
(	O
18	O
,	O
21	O
,	O
28	O
).	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
to	O
meals	O
high	O
in	O
saturated	O
fat	O
would	O
blunt	O
the	O
postprandial	O
inflammatory	O
response	O
in	O
human	B-OG
subjects	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
postprandial	O
inflammatory	O
effect	O
of	O
a	O
high	O
-	O
saturated	O
fat	O
meal	O
using	O
PO	O
with	O
and	O
without	O
the	O
addition	O
of	O
MFGM	O
in	O
overweight	O
and	O
obese	O
adults	O
.	O

We	O
hypothesised	O
that	O
consuming	O
a	O
high	O
-	O
fat	O
PO	O
+	O
MFGM	O
meal	O
would	O
result	O
in	O
lower	O
pro	O
-	O
inflammatory	O
serum	O
markers	O
compared	O
with	O
the	O
isoenergetic	O
PO	O
meal	O
.	O

Materials	O
and	O
methods	O

Participants	O

A	O
total	O
of	O
seventeen	O
adult	O
men	B-OG
and	O
nineteen	O
adult	O
women	B-OG
(	O
total	O
of	O
thirty	O
-	O
six	O
participants	O
)	O
were	O
recruited	O
from	O
the	O
Davis	O
and	O
greater	O
Sacramento	O
areas	O
of	O
California	O
to	O
participate	O
in	O
this	O
study	O
.	O

To	O
qualify	O
,	O
individuals	O
had	O
to	O
be	O
between	O
18	O
and	O
65	O
years	O
of	O
age	O
,	O
and	O
either	O
be	O
overweight	O
according	O
to	O
their	O
BMI	O
(	O
25	O
–	O
29	O
·	O
9	O
kg	O
/	O
m2	O
)	O
plus	O
have	O
two	O
or	O
more	O
MetS	B-DS
traits	O
according	O
to	O
the	O
definition	O
of	O
the	O
American	O
Heart	O
Association	O
or	O
simply	O
be	O
obese	O
according	O
to	O
their	O
BMI	O
(	O
30	O
–	O
39	O
·	O
9	O
kg	O
/	O
m2	O
)	O
and	O
have	O
any	O
number	O
of	O
MetS	B-DS
traits	O
.	O

The	O
MetS	B-DS
is	O
defined	O
by	O
having	O
three	O
or	O
more	O
of	O
the	O
following	O
traits	O
:	O
waist	O
circumference	O
>	O
40	O
inches	O
(>	O
102	O
cm	O
)	O
for	O
men	B-OG
and	O
35	O
inches	O
(>	O
89	O
cm	O
)	O
inches	O
for	O
women	B-OG
;	O
fasting	O
plasma	O
TAG	O
≥	O
150	O
mg	O
/	O
dl	O
(≥	O
1	O
·	O
70	O
mmol	O
/	O
l	O
);	O
fasting	O
plasma	O
HDL	O
-	O
cholesterol	O
<	O
40	O
mg	O
/	O
dl	O
(<	O
1	O
·	O
04	O
mmol	O
/	O
l	O
)	O
for	O
men	B-OG
and	O
<	O
50	O
mg	O
/	O
dl	O
(<	O
1	O
·	O
30	O
mmol	O
/	O
l	O
)	O
for	O
women	B-OG
;	O
blood	O
pressure	O
≥	O
130	O
/	O
85	O
mmHg	O
;	O
and	O
fasting	O
glucose	O
≥	O
100	O
mg	O
/	O
dl	O
(≥	O
5	O
·	O
56	O
mmol	O
/	O
l	O
)(	O
29	O
).	O

Individuals	O
were	O
excluded	O
from	O
participation	O
for	O
the	O
following	O
reasons	O
:	O
diagnosis	O
of	O
immune	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
gastrointestinal	B-DS
disorders	I-DS
,	O
cancer	B-DS
,	O
type	B-DS
2	I-DS
diabetes	I-DS
,	O
eating	B-DS
disorder	I-DS
,	O
allergies	B-DS
to	O
the	O
provided	O
study	O
foods	O
,	O
poor	O
vein	O
accessibility	O
according	O
to	O
the	O
research	O
phlebotomist	O
,	O
or	O
a	O
body	O
-	O
weight	O
change	O
greater	O
than	O
10	O
%	O
over	O
the	O
past	O
6	O
months	O
.	O

Individuals	O
were	O
excluded	O
from	O
participation	O
if	O
they	O
used	O
the	O
following	O
:	O
weight	O
loss	O
medications	O
;	O
daily	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
);	O
anti	O
-	O
inflammatory	O
supplements	O
;	O
corticoid	O
steroids	O
;	O
tobacco	O
;	O
change	O
in	O
hormonal	O
birth	O
control	O
regimen	O
with	O
the	O
past	O
6	O
months	O
;	O
initiation	O
of	O
statins	O
in	O
past	O
3	O
months	O
.	O

Because	O
of	O
possible	O
confounding	O
effects	O
on	O
inflammatory	O
outcomes	O
,	O
dietary	O
exclusion	O
criteria	O
were	O
as	O
follows	O
:	O
>	O
1	O
serving	O
of	O
fish	B-OG
/	O
week	O
;	O
>	O
14	O
g	O
fibre	O
/	O
1000	O
kcal	O
(	O
4184	O
kJ	O
)	O
per	O
d	O
;	O
<	O
16	O
:	O
1	O
of	O
total	O
dietary	O
n	O
-	O
6	O
:	O
n	O
-	O
3	O
ratio	O
;	O
>	O
1	O
%	O
of	O
daily	O
energy	O
as	O
trans	O
-	O
fats	O
;	O
and	O
a	O
vegetarian	O
diet	O
pattern	O
.	O

If	O
individuals	O
had	O
initiated	O
an	O
exercise	O
programme	O
within	O
the	O
past	O
6	O
months	O
,	O
planned	O
to	O
become	O
pregnant	O
within	O
the	O
next	O
6	O
months	O
,	O
or	O
were	O
already	O
pregnant	O
or	O
lactating	O
,	O
they	O
were	O
not	O
enrolled	O
in	O
the	O
study	O
.	O

To	O
determine	O
enrolment	O
eligibility	O
,	O
questionnaires	O
were	O
administered	O
regarding	O
health	O
history	O
,	O
diet	O
and	O
medication	O
.	O

An	O
online	O
FFQ	O
was	O
used	O
to	O
assess	O
dietary	O
intake	O
and	O
a	O
fasting	O
blood	O
sample	O
was	O
drawn	O
for	O
the	O
analysis	O
of	O
blood	O
lipids	O
and	O
glucose	O
.	O

Additional	O
anthropometric	O
measurements	O
were	O
taken	O
during	O
the	O
screening	O
visit	O
to	O
determine	O
MetS	B-DS
traits	O
(	O
weight	O
,	O
height	O
,	O
and	O
waist	O
circumference	O
).	O

This	O
study	O
was	O
approved	O
from	O
an	O
ethical	O
standpoint	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
University	O
of	O
California	O
,	O
Davis	O
.	O

Informed	O
consent	O
was	O
given	O
in	O
writing	O
by	O
all	O
study	O
participants	O
prior	O
to	O
starting	O
the	O
study	O
protocol	O
.	O

The	O
study	O
was	O
registered	O
at	O
clinicaltrials	O
.	O
gov	O
under	O
NCT01811329	O
.	O

Study	O
design	O

Two	O
isoenergetic	O
test	O
meals	O
were	O
consumed	O
by	O
the	O
participants	O
in	O
a	O
randomised	O
,	O
double	O
-	O
blinded	O
,	O
two	O
-	O
way	O
cross	O
-	O
over	O
design	O
.	O

A	O
high	O
-	O
fat	O
PO	O
meal	O
was	O
compared	O
against	O
a	O
high	O
-	O
fat	O
PO	O
meal	O
with	O
the	O
addition	O
of	O
MFGM	O
(	O
PO	O
+	O
MFGM	O
).	O

Participants	O
were	O
assigned	O
to	O
test	O
meal	O
order	O
using	O
a	O
random	O
number	O
generator	O
which	O
randomly	O
returned	O
either	O
a	O
0	O
or	O
1	O
,	O
with	O
a	O
0	O
being	O
assigned	O
to	O
PO	O
first	O
followed	O
by	O
PO	O
+	O
MFGM	O
second	O
,	O
and	O
a	O
1	O
being	O
assigned	O
to	O
PO	O
+	O
MFGM	O
first	O
followed	O
by	O
PO	O
second	O
.	O

Test	O
meals	O
were	O
consumed	O
in	O
random	O
order	O
on	O
different	O
test	O
days	O
separated	O
by	O
a	O
washout	O
phase	O
of	O
minimally	O
1	O
week	O
and	O
maximally	O
2	O
weeks	O
to	O
avoid	O
any	O
carry	O
-	O
over	O
effects	O
.	O

After	O
each	O
washout	O
,	O
participants	O
consumed	O
the	O
alternate	O
test	O
meal	O
.	O

To	O
limit	O
confounding	O
effects	O
,	O
the	O
consumption	O
of	O
anti	O
-	O
inflammatory	O
supplements	O
,	O
alcohol	O
or	O
NSAID	O
was	O
not	O
permitted	O
for	O
72	O
h	O
before	O
each	O
test	O
day	O
.	O

At	O
24	O
h	O
prior	O
to	O
the	O
test	O
day	O
,	O
vigorous	O
exercise	O
was	O
prohibited	O
to	O
avoid	O
increasing	O
inflammatory	O
markers	O
and	O
conversely	O
consumption	O
of	O
seafood	O
was	O
not	O
allowed	O
to	O
avoid	O
a	O
suppression	O
of	O
inflammatory	O
markers	O
.	O

To	O
ensure	O
compliance	O
,	O
participants	O
filled	O
out	O
a	O
1	O
-	O
d	O
food	O
record	O
for	O
the	O
24	O
h	O
prior	O
to	O
each	O
test	O
day	O
.	O

The	O
dietary	O
records	O
were	O
analysed	O
using	O
the	O
Nutrition	O
Data	O
System	O
for	O
Research	O
(	O
NDSR	O
;	O
University	O
of	O
Minnesota	O
).	O

Participants	O
arrived	O
at	O
the	O
Western	O
Human	B-OG
Nutrition	O
Research	O
Center	O
after	O
a	O
10	O
–	O
12	O
h	O
fast	O
on	O
each	O
test	O
day	O
.	O

The	O
24	O
h	O
diet	O
record	O
was	O
collected	O
and	O
participants	O
were	O
asked	O
to	O
complete	O
a	O
modified	O
gastrointestinal	O
questionnaire	O
(	O
30	O
).	O

A	O
fasted	O
blood	O
sample	O
was	O
drawn	O
via	O
venepuncture	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
weight	O
and	O
waist	O
circumference	O
were	O
measured	O
.	O

The	O
dietary	O
test	O
meal	O
was	O
then	O
consumed	O
completely	O
within	O
20	O
min	O
.	O

Postprandial	O
blood	O
draws	O
were	O
conducted	O
at	O
1	O
,	O
3	O
and	O
6	O
h	O
.	O

These	O
time	O
points	O
were	O
determined	O
based	O
on	O
previous	O
postprandial	O
clinical	O
trials	O
observing	O
a	O
peak	O
in	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
concentrations	O
around	O
3	O
–	O
6	O
h	O
after	O
consuming	O
a	O
high	O
-	O
fat	O
meal	O
(	O
6	O
,	O
31	O
).	O

Consumption	O
of	O
any	O
food	O
other	O
than	O
the	O
test	O
meal	O
was	O
not	O
permitted	O
,	O
but	O
bottled	O
water	O
was	O
offered	O
throughout	O
the	O
test	O
day	O
.	O

Participants	O
were	O
offered	O
the	O
option	O
to	O
stay	O
at	O
the	O
research	O
facility	O
or	O
leave	O
between	O
blood	O
draws	O
via	O
car	O
to	O
limit	O
physical	O
activity	O
and	O
had	O
to	O
return	O
15	O
min	O
before	O
their	O
scheduled	O
blood	O
draw	O
to	O
allow	O
for	O
a	O
10	O
min	O
rest	O
period	O
prior	O
to	O
each	O
blood	O
draw	O
.	O

Dietary	O
challenges	O

The	O
two	O
test	O
meals	O
were	O
made	O
up	O
of	O
a	O
bagel	O
with	O
strawberry	B-OG
preserves	O
along	O
with	O
either	O
a	O
PO	O
or	O
PO	O
+	O
MFGM	O
smoothie	O
.	O

In	O
each	O
instance	O
the	O
smoothie	O
consisted	O
of	O
deionised	O
water	O
,	O
cream	O
of	O
tartar	O
,	O
PO	O
shortening	O
,	O
and	O
raspberry	O
sorbet	O
.	O

Additionally	O
,	O
the	O
PO	O
+	O
MFGM	O
smoothie	O
contained	O
BPC50	O
,	O
a	O
cream	O
-	O
derived	O
complex	O
milk	O
lipid	O
fraction	O
powder	O
(	O
β	O
serum	O
concentrate	O
)	O
that	O
is	O
a	O
proprietary	O
product	O
supplied	O
by	O
Fonterra	O
Co	O
-	O
operative	O
Group	O
Ltd	O
(	O
New	O
Zealand	O
)(	O
32	O
).	O

BPC50	O
is	O
comprised	O
of	O
the	O
following	O
(%	O
w	O
/	O
w	O
):	O
52	O
%	O
protein	O
of	O
which	O
13	O
·	O
2	O
%	O
is	O
membrane	O
-	O
derived	O
protein	O
,	O
6	O
·	O
6	O
%	O
lactose	O
and	O
36	O
·	O
2	O
%	O
total	O
fat	O
(	O
22	O
·	O
5	O
%	O
TAG	O
and	O
13	O
·	O
7	O
%	O
phospholipids	O
),	O
0	O
·	O
63	O
%	O
gangliosides	O
(	O
GD3	O
),	O
and	O
5	O
·	O
2	O
%	O
ash	O
(	O
33	O
–	O
35	O
).	O

The	O
six	O
highest	O
abundant	O
MFGM	O
-	O
derived	O
proteins	O
reported	O
in	O
BPC50	O
include	O
:	O
fatty	B-GP
acid	I-GP
-	I-GP
binding	I-GP
protein	I-GP
,	O
butyrophilin	B-GP
,	O
lactadherin	B-GP
,	O
adipophilin	B-GP
,	O
xanthine	O
oxidase	O
and	O
mucin	O
(	O
35	O
).	O

The	O
PO	O
smoothie	O
contained	O
whey	O
protein	O
isolate	O
to	O
match	O
the	O
protein	O
content	O
found	O
in	O
the	O
BPC50	O
product	O
.	O

For	O
ingredient	O
details	O
,	O
see	O
Supplementary	O
Table	O
S1	O
.	O

Participants	O
were	O
instructed	O
to	O
eat	O
the	O
entire	O
meal	O
,	O
rinse	O
their	O
cup	O
with	O
water	O
,	O
and	O
drink	O
the	O
rinse	O
-	O
water	O
.	O

Each	O
test	O
meal	O
provided	O
40	O
%	O
of	O
the	O
participant	O
'	O
s	O
total	O
daily	O
energy	O
intake	O
.	O

Energy	O
intake	O
was	O
determined	O
by	O
using	O
the	O
National	O
Academy	O
of	O
Sciences	O
equation	O
from	O
the	O
Institute	O
of	O
Medicine	O
Dietary	O
Reference	O
Intake	O
(	O
36	O
).	O

To	O
determine	O
each	O
participant	O
'	O
s	O
physical	O
activity	O
level	O
the	O
Baecke	O
Physical	O
Activity	O
questionnaire	O
was	O
used	O
(	O
37	O
).	O

The	O
two	O
isoenergetic	O
test	O
meals	O
were	O
constructed	O
to	O
vary	O
less	O
than	O
0	O
·	O
2	O
%	O
in	O
macronutrients	O
and	O
provided	O
about	O
55	O
%	O
fat	O
,	O
about	O
30	O
%	O
carbohydrates	O
,	O
and	O
about	O
15	O
%	O
protein	O
.	O

Each	O
test	O
meal	O
provided	O
between	O
49	O
and	O
87	O
g	O
of	O
fat	O
depending	O
on	O
each	O
individual	O
'	O
s	O
energy	O
intake	O
,	O
61	O
–	O
107	O
g	O
of	O
carbohydrates	O
,	O
and	O
31	O
–	O
55	O
g	O
of	O
protein	O
(	O
Table	O
1	O
).	O

Test	O
meal	O
nutrient	O
composition	O
was	O
estimated	O
using	O
NDSR	O
(	O
University	O
of	O
Minnesota	O
).	O

The	O
addition	O
of	O
MFGM	O
(	O
ranging	O
from	O
53	O
·	O
2	O
to	O
93	O
·	O
1	O
g	O
depending	O
on	O
each	O
individual	O
'	O
s	O
energy	O
intake	O
)	O
replaced	O
31	O
%	O
of	O
the	O
fat	O
of	O
each	O
participant	O
'	O
s	O
meal	O
(	O
34	O
%	O
of	O
the	O
total	O
energy	O
).	O
Table	O
1	O
.	O
Nutrient	O
composition	O
of	O
test	O
meals	O
†(	O
Mean	O
values	O
and	O
standard	O
deviations	O
)	O
PO	O
mealPO	O
+	O
MFGM	O
mealMean	O
sd	O
Mean	O
sd	O
Energy	O
(	O
kcal	O
)	O
1088	O
·	O
1189	O
·	O
31088	O
·	O
1189	O
·	O
2Energy	O
(	O
kJ	O
)	O
4552	O
·	O
4791	O
·	O
84552	O
·	O
7791	O
·	O
7Total	O
carbohydrate	O
g82	O
·	O
714	O
·	O
483	O
·	O
214	O
·	O
5	O
%	O
total	O
energy30	O
·	O
40	O
·	O
030	O
·	O
60	O
·	O
0Total	O
protein	O
g42	O
·	O
57	O
·	O
4437	O
·	O
5	O
%	O
total	O
energy15	O
·	O
60	O
·	O
015	O
·	O
80	O
·	O
0Total	O
fat	O
g67	O
·	O
311	O
·	O
767	O
·	O
511	O
·	O
7	O
%	O
total	O
energy55	O
·	O
60	O
·	O
055	O
·	O
80	O
·	O
0Total	O
SFA	O
g32	O
·	O
65	O
·	O
734	O
·	O
66	O
·	O
0	O
%	O
total	O
energy27	O
·	O
00	O
·	O
028	O
·	O
60	O
·	O
0Total	O
MUFA	O
g24	O
·	O
64	O
·	O
322	O
·	O
73	O
·	O
9	O
%	O
total	O
energy20	O
·	O
30	O
·	O
018	O
·	O
80	O
·	O
0Total	O
PUFA	O
*	O
g6	O
·	O
91	O
·	O
26	O
·	O
11	O
·	O
1	O
%	O
total	O
energy5	O
·	O
70	O
·	O
05	O
·	O
10	O
·	O
0SFA	O
4	O
:	O
0	O
(	O
butyric	O
acid	O
)	O
(%)	O
000	O
·	O
20	O
·	O
0SFA	O
6	O
:	O
0	O
(	O
caproic	O
acid	O
)	O
(%)	O
000	O
·	O
20	O
·	O
0SFA	O
8	O
:	O
0	O
(	O
caprylic	O
acid	O
)	O
(%)	O
000	O
·	O
20	O
·	O
0SFA	O
10	O
:	O
0	O
(	O
capric	O
acid	O
)	O
(%)*	O
000	O
·	O
50	O
·	O
1SFA	O
12	O
:	O
0	O
(	O
lauric	O
acid	O
)	O
(%)*	O
0	O
·	O
10	O
·	O
00	O
·	O
80	O
·	O
1SFA	O
14	O
:	O
0	O
(	O
myristic	O
acid	O
)	O
(%)*	O
0	O
·	O
70	O
·	O
12	O
·	O
50	O
·	O
4SFA	O
16	O
:	O
0	O
(	O
palmitic	O
acid	O
)	O
(%)*	O
28	O
·	O
7524	O
·	O
84	O
·	O
3SFA	O
18	O
:	O
0	O
(	O
stearic	O
acid	O
)	O
(%)*	O
2	O
·	O
90	O
·	O
54	O
·	O
70	O
·	O
8MUFA	O
16	O
:	O
1	O
(	O
palmitoleic	O
acid	O
)	O
(%)*	O
0	O
·	O
20	O
·	O
00	O
·	O
50	O
·	O
1MUFA	O
18	O
:	O
1	O
(	O
oleic	O
acid	O
)	O
(%)*	O
24	O
·	O
34	O
·	O
222	O
·	O
23	O
·	O
9PUFA	O
18	O
:	O
2	O
(	O
linoleic	O
acid	O
)	O
(%)	O
6	O
·	O
61	O
·	O
15	O
·	O
10	O
·	O
9PUFA	O
18	O
:	O
3	O
(	O
linolenic	O
acid	O
)	O
(%)	O
0	O
·	O
30	O
·	O
10	O
·	O
50	O
·	O
1PO	O
,	O
palm	O
oil	O
;	O
PO	O
+	O
MFGM	O
,	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
.*	O
Significant	O
difference	O
between	O
the	O
two	O
meals	O
(	O
P	O
<	O
0	O
·	O
05	O
).†	O
Comparison	O
of	O
the	O
dietary	O
challenges	O
.	O

Nutrient	O
composition	O
obtained	O
using	O
the	O
Nutrition	O
Data	O
System	O
for	O
Research	O
(	O
NDSR	O
).	O

Test	O
meals	O
were	O
based	O
on	O
each	O
individual	O
'	O
s	O
total	O
energy	O
expenditure	O
;	O
thus	O
values	O
shown	O
are	O
average	O
of	O
all	O
test	O
meals	O
(	O
n	O
36	O
).	O

Blood	O
analyses	O

Whole	O
blood	O
was	O
drawn	O
at	O
baseline	O
,	O
and	O
at	O
1	O
,	O
3	O
and	O
6	O
h	O
after	O
the	O
meal	O
.	O

Serum	O
tubes	O
were	O
allowed	O
to	O
clot	O
at	O
room	O
temperature	O
for	O
30	O
min	O
,	O
and	O
then	O
centrifuged	O
at	O
1300	O
g	O
at	O
4	O
°	O
C	O
for	O
10	O
min	O
.	O

EDTA	O
-	O
whole	O
blood	O
tubes	O
were	O
kept	O
on	O
ice	O
during	O
and	O
after	O
blood	O
collection	O
and	O
were	O
centrifuged	O
within	O
30	O
min	O
of	O
collection	O
at	O
1300	O
g	O
at	O
4	O
°	O
C	O
for	O
10	O
min	O
.	O

After	O
centrifugation	O
,	O
the	O
serum	O
and	O
plasma	O
tubes	O
were	O
kept	O
on	O
ice	O
during	O
aliquoting	O
.	O

Subsequently	O
,	O
plasma	O
and	O
serum	O
aliquots	O
were	O
directly	O
frozen	O
at	O
–	O
70	O
°	O
C	O
until	O
analysed	O
.	O

Inflammatory	O
markers	O

Serum	O
samples	O
from	O
all	O
four	O
time	O
points	O
were	O
analysed	O
for	O
cytokine	B-GP
concentrations	O
(	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
2	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
TNFα	B-GP
,	O
monocyte	B-GP
chemotactic	I-GP
protein	I-GP
-	I-GP
1	I-GP
),	O
as	O
well	O
as	O
the	O
vascular	O
injury	O
molecules	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
(	O
CRP	B-GP
),	O
serum	B-GP
amyloid	I-GP
A	I-GP
,	O
soluble	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
(	O
sICAM	B-GP
)	O
and	O
soluble	O
vascular	B-GP
adhesion	I-GP
molecule	I-GP
.	O

Plasma	O
was	O
used	O
to	O
measure	O
IL	B-GP
-	I-GP
18	I-GP
concentrations	O
.	O

A	O
commercially	O
available	O
Multi	O
Spot	O
ELISA	O
kit	O
was	O
used	O
to	O
quantify	O
the	O
concentrations	O
of	O
these	O
markers	O
(	O
SECTOR	O
Imager	O
2400	O
;	O
Meso	O
Scale	O
Discovery	O
).	O

The	O
protocol	O
was	O
followed	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Briefly	O
,	O
pre	O
-	O
coated	O
plates	O
with	O
capture	O
antibodies	B-GP
were	O
incubated	O
with	O
25	O
–	O
50	O
µl	O
of	O
serum	O
or	O
plasma	O
.	O

After	O
washing	O
the	O
plates	O
a	O
labelled	O
detection	O
antibody	B-GP
was	O
added	O
.	O

Upon	O
electrochemical	O
stimulation	O
the	O
bound	O
detection	O
antibodies	B-GP
emit	O
light	O
,	O
which	O
is	O
measured	O
by	O
the	O
plate	O
reader	O
to	O
quantify	O
the	O
amount	O
of	O
each	O
protein	O
of	O
interest	O
.	O

Cortisol	O

Serum	O
cortisol	O
was	O
measured	O
at	O
all	O
times	O
points	O
using	O
the	O
DetectX	O
Cortisol	O
Enzyme	O
Immunoassay	O
kit	O
(	O
Arbor	O
Assays	O
).	O

Briefly	O
,	O
a	O
cortisol	O
–	O
peroxidase	B-GP
conjugate	O
and	O
a	O
monoclonal	O
cortisol	O
antibody	B-GP
were	O
added	O
to	O
a	O
pre	O
-	O
coated	O
ninety	O
-	O
six	O
-	O
well	O
plate	O
.	O

Upon	O
incubation	O
,	O
serum	O
samples	O
were	O
added	O
to	O
each	O
well	O
and	O
allowed	O
to	O
bind	O
with	O
the	O
cortisol	O
–	O
peroxidase	B-GP
conjugate	O
.	O

The	O
total	O
amount	O
of	O
cortisol	O
present	O
in	O
each	O
sample	O
was	O
then	O
calculated	O
based	O
on	O
the	O
absorbance	O
detected	O
by	O
the	O
reader	O
.	O

Metabolic	O
parameters	O

At	O
each	O
time	O
point	O
plasma	O
glucose	O
,	O
insulin	B-GP
,	O
and	O
a	O
lipid	O
panel	O
including	O
TAG	O
,	O
total	O
cholesterol	O
,	O
HDL	O
-	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
,	O
HDL	O
:	O
LDL	O
ratio	O
,	O
and	O
non	O
-	O
HDL	O
-	O
cholesterol	O
were	O
assessed	O
by	O
standard	O
clinical	O
techniques	O
in	O
the	O
clinical	O
laboratory	O
of	O
University	O
of	O
California	O
Medical	O
Center	O
(	O
Sacramento	O
,	O
CA	O
).	O

Clinical	O
characteristics	O

Body	O
weight	O
,	O
height	O
,	O
waist	O
circumference	O
,	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
measured	O
on	O
each	O
test	O
day	O
.	O

Body	O
weight	O
was	O
measured	O
with	O
a	O
calibrated	O
scale	O
(	O
6002	O
Wheelchair	O
Scale	O
;	O
Scale	O
-	O
tronix	O
).	O

Waist	O
circumference	O
was	O
measured	O
in	O
the	O
standing	O
position	O
with	O
measurements	O
midway	O
between	O
the	O
lateral	O
lower	O
rib	O
margin	O
and	O
the	O
ileac	O
crest	O
(	O
QM2000	O
Measure	O
Mate	O
;	O
QuickMedical	O
).	O

Height	O
was	O
measured	O
with	O
a	O
wall	O
-	O
mounted	O
stadiometer	O
(	O
Ayrton	O
Stadiometer	O
Model	O
S100	O
;	O
Ayrton	O
Corporation	O
).	O

Blood	O
pressure	O
and	O
resting	O
heart	O
rate	O
were	O
taken	O
in	O
the	O
upright	O
seated	O
position	O
using	O
the	O
appropriately	O
sized	O
cuff	O
(	O
Carescape	O
V100	O
with	O
Critikon	O
Dura	O
-	O
cuf	O
for	O
either	O
adults	O
or	O
large	O
adults	O
;	O
GE	O
Medical	O
Instruments	O
).	O

Total	O
fat	O
mass	O
and	O
lean	O
mass	O
were	O
assessed	O
using	O
dual	O
-	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
Lunar	O
Prodigy	O
instrument	O
;	O
GE	O
Medical	O
Instruments	O
).	O

Statistical	O
analysis	O

The	O
sample	O
size	O
was	O
calculated	O
based	O
on	O
the	O
primary	O
outcome	O
marker	O
IL	B-GP
-	I-GP
6	I-GP
using	O
the	O
means	O
and	O
standard	O
deviations	O
from	O
a	O
similar	O
human	B-OG
study	O
with	O
overweight	O
men	B-OG
at	O
risk	O
for	O
developing	O
the	O
MetS	B-DS
(	O
31	O
).	O

To	O
ensure	O
95	O
%	O
confidence	O
of	O
the	O
results	O
and	O
80	O
%	O
power	O
the	O
sample	O
size	O
calculation	O
indicated	O
that	O
thirty	O
-	O
six	O
participants	O
would	O
be	O
needed	O
.	O

Statistical	O
analyses	O
were	O
conducted	O
on	O
SPSS	O
version	O
20	O
.	O
0	O
software	O
for	O
Macintosh	O
(	O
SPSS	O
).	O

Differences	O
were	O
considered	O
significant	O
at	O
P	O
<	O
0	O
·	O
05	O
.	O

Normality	O
was	O
established	O
visually	O
and	O
numerically	O
using	O
histograms	O
,	O
Q	O
–	O
Q	O
plots	O
and	O
the	O
Shapiro	O
–	O
Wilk	O
test	O
.	O

Data	O
were	O
transformed	O
as	O
needed	O
.	O

When	O
concentrations	O
for	O
markers	O
were	O
below	O
the	O
lower	O
limit	O
of	O
detection	O
(	O
LLOD	O
)	O
(	O
IL	B-GP
-	I-GP
10	I-GP
;	O
23	O
%	O
and	O
IL	B-GP
-	I-GP
6	I-GP
;	O
9	O
%)	O
for	O
<	O
25	O
%	O
of	O
the	O
samples	O
,	O
the	O
value	O
was	O
calculated	O
as	O
the	O
LLOD	O
divided	O
by	O
10	O
.	O

When	O
concentrations	O
for	O
markers	O
were	O
below	O
the	O
LLOD	O
for	O
>	O
25	O
%	O
of	O
the	O
samples	O
,	O
the	O
data	O
were	O
excluded	O
from	O
statistical	O
analyses	O
(	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
4	I-GP
).	O

Cases	O
with	O
values	O
more	O
than	O
three	O
box	O
lengths	O
from	O
the	O
75th	O
percentile	O
or	O
25th	O
percentile	O
were	O
deemed	O
outliers	O
and	O
removed	O
from	O
all	O
analyses	O
;	O
this	O
only	O
applied	O
to	O
sICAM	B-GP
where	O
two	O
subjects	O
were	O
excluded	O
.	O

To	O
determine	O
if	O
dietary	O
differences	O
existed	O
between	O
test	O
meal	O
composition	O
and	O
baseline	O
analyte	O
concentrations	O
a	O
paired	O
t	O
test	O
was	O
used	O
.	O

A	O
mixed	O
linear	O
model	O
was	O
performed	O
with	O
treatment	O
and	O
time	O
as	O
fixed	O
factors	O
,	O
participants	O
as	O
the	O
random	O
effect	O
and	O
treatment	O
×	O
time	O
as	O
the	O
interaction	O
term	O
.	O

If	O
time	O
was	O
significant	O
,	O
multiple	O
-	O
comparison	O
post	O
hoc	O
analysis	O
with	O
Bonferroni	O
correction	O
was	O
carried	O
out	O
to	O
compare	O
the	O
concentrations	O
at	O
0	O
–	O
1	O
h	O
,	O
0	O
–	O
3	O
h	O
,	O
0	O
–	O
6	O
h	O
,	O
1	O
–	O
3	O
h	O
,	O
1	O
–	O
6	O
h	O
,	O
and	O
3	O
–	O
6	O
h	O
.	O

The	O
incremental	O
AUC	O
(	O
iAUC	O
,	O
area	O
above	O
baseline	O
)	O
and	O
decremental	O
(	O
area	O
below	O
baseline	O
)	O
using	O
the	O
conventional	O
trapezoid	O
method	O
were	O
used	O
to	O
compare	O
postprandial	O
responses	O
between	O
test	O
meals	O
(	O
38	O
).	O

The	O
iAUC	O
was	O
chosen	O
over	O
the	O
total	O
AUC	O
because	O
it	O
reflects	O
the	O
postprandial	O
rise	O
of	O
these	O
metabolite	O
concentrations	O
above	O
the	O
non	O
-	O
zero	O
fasting	O
value	O
(	O
39	O
).	O

iAUC	O
between	O
test	O
meals	O
were	O
compared	O
by	O
one	O
-	O
way	O
ANOVA	O
.	O

To	O
determine	O
if	O
pre	O
-	O
existing	O
clinical	O
conditions	O
affected	O
the	O
inflammatory	O
responses	O
to	O
the	O
test	O
meals	O
,	O
secondary	O
analyses	O
were	O
conducted	O
.	O

Participants	O
were	O
coded	O
as	O
having	O
high	O
or	O
low	O
CRP	B-GP
levels	O
based	O
on	O
their	O
baseline	O
levels	O
prior	O
to	O
receiving	O
either	O
test	O
meal	O
treatment	O
.	O

High	O
CRP	B-GP
was	O
defined	O
as	O
a	O
concentration	O
≥	O
3	O
mg	O
/	O
l	O
(	O
n	O
17	O
),	O
low	O
CRP	B-GP
was	O
defined	O
as	O
<	O
3	O
mg	O
/	O
l	O
(	O
n	O
19	O
)(	O
40	O
).	O

Baseline	O
characteristics	O
of	O
each	O
CRP	B-GP
group	O
can	O
be	O
found	O
in	O
Table	O
2	O
.	O

ANCOVA	O
was	O
used	O
to	O
identify	O
statistically	O
significant	O
differences	O
in	O
postprandial	O
inflammatory	O
markers	O
between	O
test	O
meals	O
using	O
CRP	B-GP
as	O
the	O
covariate	O
variable	O
.	O
Table	O
2	O
.	O
Participant	O
baseline	O
characteristics	O
*(	O
Mean	O
values	O
and	O
standard	O
deviations	O
)	O
All	O
participantsLow	O
CRP	B-GP
‡	O
High	O
CRP	B-GP
‡	O
Mean	O
sd	O
MetS	B-DS
criteria	O
†	O
Mean	O
sd	O
Mean	O
sd	O
Age	O
(	O
years	O
)	O
42	O
·	O
914	O
·	O
042	O
·	O
413	O
·	O
643	O
·	O
614	O
·	O
9Weight	O
(	O
kg	O
)	O
92	O
·	O
912	O
·	O
293	O
·	O
511	O
·	O
992	O
·	O
212	O
·	O
8Height	O
(	O
m	O
)	O
1	O
·	O
70	O
·	O
11	O
·	O
70	O
·	O
11	O
·	O
70	O
·	O
1BMI	O
(	O
kg	O
/	O
m2	O
)	O
31	O
·	O
72	O
·	O
631	O
·	O
92	O
·	O
631	O
·	O
52	O
·	O
5Total	O
body	O
fat	O
(%)	O
36	O
·	O
77	O
·	O
834	O
·	O
28	O
·	O
339	O
·	O
56	O
·	O
3	O
Total	O
body	O
fat	O
,	O
male	O
(%)§	O
31	O
·	O
06	O
·	O
228	O
·	O
54	O
·	O
335	O
·	O
56	O
·	O
8	O
Total	O
body	O
fat	O
,	O
female	O
(%)§	O
41	O
·	O
94	O
·	O
942	O
·	O
15	O
·	O
141	O
·	O
75	O
·	O
0Android	O
fat	O
(	O
g	O
)	O
3262	O
·	O
9799	O
·	O
940	O
·	O
56	O
·	O
746	O
·	O
14	O
·	O
2	O
Android	O
fat	O
,	O
male	O
(	O
g	O
)	O
3370	O
·	O
8934	O
·	O
137	O
·	O
25	O
·	O
745	O
·	O
23	O
·	O
3	O
Android	O
fat	O
,	O
female	O
(	O
g	O
)	O
3166	O
·	O
3669	O
·	O
045	O
·	O
05	O
·	O
346	O
·	O
74	O
·	O
7Gynoid	O
fat	O
(	O
g	O
)	O
5353	O
·	O
31452	O
·	O
036	O
·	O
98	O
·	O
639	O
·	O
57	O
·	O
0	O
Gynoid	O
fat	O
,	O
male	O
(	O
g	O
)	O
4829	O
·	O
21325	O
·	O
831	O
·	O
25	O
·	O
033	O
·	O
55	O
·	O
3	O
Gynoid	O
fat	O
,	O
female	O
(	O
g	O
)	O
5822	O
·	O
11430	O
·	O
244	O
·	O
85	O
·	O
742	O
·	O
75	O
·	O
6WC	O
(	O
inches	O
)	O
39	O
·	O
33	O
·	O
238	O
·	O
82	O
·	O
939	O
·	O
93	O
·	O
4	O
WC	O
,	O
male	O
(	O
inches	O
)	O
41	O
·	O
13	O
·	O
1	O
>	O
4040	O
·	O
22	O
·	O
942	O
·	O
82	O
·	O
9	O
WC	O
,	O
female	O
(	O
inches	O
)	O
37	O
·	O
72	O
·	O
2	O
>	O
3536	O
·	O
91	O
·	O
638	O
·	O
22	O
·	O
4WC	O
(	O
cm	O
)	O
99	O
·	O
88	O
·	O
198	O
·	O
67	O
·	O
4101	O
·	O
38	O
·	O
6	O
WC	O
,	O
male	O
(	O
cm	O
)	O
104	O
·	O
47	O
·	O
9	O
>	O
102102	O
·	O
17	O
·	O
4108	O
·	O
77	O
·	O
4	O
WC	O
,	O
female	O
(	O
cm	O
)	O
95	O
·	O
85	O
·	O
6	O
>	O
8993	O
·	O
74	O
·	O
197	O
·	O
06	O
·	O
1Systolic	O
BP	O
(	O
mmHg	O
)	O
123	O
·	O
913	O
·	O
6	O
≥	O
130123	O
·	O
19	O
·	O
5124	O
·	O
817	O
·	O
4Diastolic	O
BP	O
(	O
mmHg	O
)	O
75	O
·	O
010	O
·	O
3	O
≥	O
8576	O
·	O
09	O
·	O
273	O
·	O
911	O
·	O
6HDL	O
-	O
cholesterol	O
mg	O
/	O
dl48	O
·	O
314	O
·	O
148	O
·	O
414	O
·	O
248	O
·	O
214	O
·	O
4	O
mmol	O
/	O
l1	O
·	O
250	O
·	O
371	O
·	O
250	O
·	O
371	O
·	O
250	O
·	O
37	O
HDL	O
-	O
cholesterol	O
,	O
male	O
mg	O
/	O
dl43	O
·	O
211	O
·	O
7	O
<	O
4042	O
·	O
513	O
·	O
744	O
·	O
57	O
·	O
8	O
mmol	O
/	O
l1	O
·	O
120	O
·	O
30	O
<	O
1	O
·	O
041	O
·	O
100	O
·	O
351	O
·	O
150	O
·	O
20	O
HDL	O
-	O
cholesterol	O
,	O
female	O
mg	O
/	O
dl52	O
·	O
914	O
·	O
7	O
<	O
5056	O
·	O
510	O
·	O
950	O
·	O
316	O
·	O
9	O
mmol	O
/	O
l1	O
·	O
370	O
·	O
38	O
<	O
1	O
·	O
301	O
·	O
460	O
·	O
281	O
·	O
300	O
·	O
44Fasting	O
glucose	O
mg	O
/	O
dl91	O
·	O
07	O
·	O
4	O
≥	O
10092	O
·	O
07	O
·	O
889	O
·	O
97	O
·	O
1	O
mmol	O
/	O
l5	O
·	O
060	O
·	O
41	O
≥	O
5	O
·	O
565	O
·	O
110	O
·	O
434	O
·	O
990	O
·	O
39Fasting	O
TAG	O
mg	O
/	O
dl122	O
·	O
557	O
·	O
8	O
≥	O
150106	O
·	O
041	O
·	O
1140	O
·	O
968	O
·	O
7	O
mmol	O
/	O
l1	O
·	O
380	O
·	O
65	O
≥	O
1	O
·	O
701	O
·	O
200	O
·	O
461	O
·	O
590	O
·	O
78MetS	O
,	O
metabolic	B-DS
syndrome	I-DS
;	O
CRP	B-GP
,	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
;	O
WC	O
,	O
waist	O
circumference	O
;	O
BP	O
,	O
blood	O
pressure	O
.*	O
Measurements	O
taken	O
at	O
screening	O
visit	O
(	O
n	O
36	O
).†	O
MetS	B-DS
as	O
defined	O
by	O
the	O
American	O
Heart	O
Association	O
.‡	O
Low	O
baseline	O
CRP	B-GP
n	O
19	O
;	O
high	O
baseline	O
CRP	B-GP
n	O
17	O
.§	O
Male	O
n	O
17	O
,	O
female	O
n	O
19	O
.	O

Results	O

Participant	O
characteristics	O

After	O
screening	O
207	O
participants	O
,	O
thirty	O
-	O
eight	O
were	O
enrolled	O
to	O
start	O
the	O
study	O
(	O
Fig	O
.	O
1	O
).	O

Thirty	O
-	O
six	O
participants	O
completed	O
both	O
postprandial	O
test	O
days	O
.	O

The	O
two	O
participants	O
who	O
did	O
not	O
finish	O
the	O
trial	O
were	O
disqualified	O
due	O
to	O
scheduling	O
difficulties	O
and	O
the	O
initiation	O
of	O
medication	O
that	O
could	O
confound	O
the	O
results	O
.	O

Each	O
participant	O
was	O
randomly	O
assigned	O
to	O
one	O
test	O
meal	O
and	O
after	O
a	O
1	O
-	O
to	O
2	O
-	O
week	O
washout	O
period	O
,	O
they	O
were	O
crossed	O
-	O
over	O
to	O
the	O
alternate	O
test	O
meal	O
.	O

The	O
majority	O
of	O
the	O
study	O
population	O
was	O
Caucasian	O
(	O
67	O
%)	O
or	O
Hispanic	O
(	O
28	O
%).	O

Out	O
of	O
the	O
total	O
thirty	O
-	O
six	O
participants	O
,	O
six	O
were	O
overweight	O
with	O
two	O
MetS	B-DS
traits	O
,	O
three	O
were	O
overweight	O
with	O
three	O
or	O
more	O
MetS	B-DS
traits	O
,	O
twenty	O
-	O
one	O
were	O
obese	O
with	O
zero	O
to	O
two	O
MetS	B-DS
traits	O
,	O
and	O
six	O
were	O
obese	O
with	O
three	O
MetS	B-DS
traits	O
.	O

The	O
baseline	O
characteristics	O
of	O
the	O
participants	O
are	O
shown	O
in	O
Table	O
2	O
.	O
Fig	O
.	O
1	O
.	O
Enrolment	O
and	O
follow	O
-	O
up	O
of	O
participants	O
in	O
the	O
randomised	O
cross	O
-	O
over	O
trial	O
.	O

PO	O
,	O
palm	O
oil	O
;	O
PO	O
+	O
MFGM	O
,	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
.	O

Dietary	O
challenge	O

Participants	O
consumed	O
two	O
test	O
meals	O
,	O
a	O
high	O
-	O
fat	O
PO	O
test	O
meal	O
and	O
a	O
high	O
-	O
fat	O
PO	O
+	O
MFGM	O
test	O
meal	O
.	O

The	O
meals	O
(	O
Table	O
1	O
)	O
were	O
isoenergetic	O
and	O
comparable	O
for	O
macronutrient	O
composition	O
,	O
not	O
varying	O
by	O
more	O
than	O
0	O
·	O
2	O
%	O
for	O
carbohydrates	O
,	O
protein	O
or	O
fat	O
.	O

The	O
total	O
weight	O
of	O
SFA	O
and	O
MUFA	O
did	O
not	O
differ	O
between	O
the	O
PO	O
v	O
.	O

PO	O
+	O
MFGM	O
test	O
meals	O
.	O

However	O
,	O
the	O
PO	O
meal	O
contained	O
a	O
significantly	O
higher	O
total	O
amount	O
of	O
PUFA	O
compared	O
with	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
.	O

The	O
relative	O
abundance	O
of	O
18	O
:	O
2n	O
-	O
6	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
test	O
meals	O
;	O
however	O
,	O
since	O
18	O
:	O
2n	O
-	O
6	O
is	O
the	O
predominant	O
PUFA	O
in	O
the	O
two	O
meals	O
,	O
and	O
since	O
the	O
PO	O
meal	O
had	O
higher	O
total	O
PUFA	O
,	O
the	O
PO	O
meal	O
had	O
a	O
higher	O
total	O
amount	O
of	O
18	O
:	O
2n	O
-	O
6	O
.	O

The	O
relative	O
abundances	O
of	O
specific	O
SFA	O
and	O
MUFA	O
were	O
significantly	O
different	O
:	O
the	O
PO	O
+	O
MFGM	O
meal	O
had	O
more	O
10	O
:	O
0	O
,	O
12	O
:	O
0	O
,	O
14	O
:	O
0	O
,	O
18	O
:	O
0	O
and	O
18	O
:	O
1n	O
-	O
9	O
whereas	O
the	O
PO	O
meal	O
had	O
more	O
16	O
:	O
0	O
and	O
16	O
:	O
1n	O
-	O
7	O
.	O

These	O
differences	O
in	O
relative	O
abundances	O
of	O
fatty	O
acids	O
are	O
reflective	O
of	O
the	O
composition	O
of	O
PO	O
,	O
which	O
is	O
enriched	O
in	O
palmitate	O
(	O
16	O
:	O
0	O
),	O
and	O
MFGM	O
,	O
which	O
is	O
enriched	O
in	O
medium	O
-	O
chain	O
SFA	O
characteristic	O
of	O
dairy	O
fat	O
.	O

Metabolic	O
parameters	O

There	O
was	O
a	O
time	O
×	O
treatment	O
interaction	O
for	O
total	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
04	O
),	O
HDL	O
-	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
01	O
),	O
TAG	O
(	O
P	O
<	O
0	O
·	O
0005	O
),	O
non	O
-	O
HDL	O
-	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
04	O
)	O
and	O
insulin	B-GP
(	O
P	O
<	O
0	O
·	O
0005	O
)	O
(	O
Table	O
3	O
).	O

Among	O
these	O
lipid	O
makers	O
,	O
the	O
greater	O
change	O
in	O
total	O
cholesterol	O
was	O
observed	O
in	O
response	O
to	O
the	O
PO	O
test	O
meal	O
;	O
there	O
was	O
a	O
5	O
%	O
increase	O
from	O
0	O
to	O
1	O
h	O
as	O
well	O
as	O
from	O
0	O
to	O
6	O
h	O
.	O

HDL	O
-	O
cholesterol	O
increased	O
from	O
0	O
to	O
1	O
h	O
by	O
4	O
%	O
and	O
decreased	O
from	O
1	O
to	O
3	O
h	O
by	O
4	O
%	O
in	O
response	O
to	O
the	O
PO	O
test	O
meal	O
.	O

In	O
response	O
to	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
,	O
TAG	O
concentration	O
increased	O
by	O
104	O
%	O
from	O
0	O
to	O
3	O
h	O
and	O
non	O
-	O
HDL	O
-	O
cholesterol	O
concentration	O
increased	O
by	O
22	O
%	O
from	O
0	O
to	O
1	O
h	O
.	O
Table	O
3	O
.	O
Concentrations	O
of	O
metabolic	O
markers	O
with	O
significant	O
interaction	O
effects	O
(	O
Mean	O
values	O
and	O
standard	O
deviations	O
)	O
Time	O
point0	O
h1	O
h3	O
h6	O
hMean	O
sd	O
Mean	O
sd	O
Mean	O
sd	O
Mean	O
sd	O
Time	O
×	O
treatment	O
:	O
PTotal	O
cholesterol	O
(	O
mg	O
/	O
dl	O
)	O
0	O
·	O
04	O
PO	O
meal194	O
·	O
938	O
·	O
5204	O
·	O
2	O
*	O
40	O
·	O
8201	O
·	O
4	O
*	O
39	O
·	O
9203	O
·	O
9	O
*	O
39	O
·	O
6	O
PO	O
+	O
MFGM	O
meal198	O
·	O
737	O
·	O
6199	O
·	O
737	O
·	O
6207	O
·	O
137	O
·	O
4203	O
·	O
735	O
·	O
8Total	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O
0	O
·	O
04	O
PO	O
meal5	O
·	O
051	O
·	O
005	O
·	O
29	O
*	O
1	O
·	O
065	O
·	O
22	O
*	O
1	O
·	O
035	O
·	O
28	O
*	O
1	O
·	O
03	O
PO	O
+	O
MFGM	O
meal5	O
·	O
150	O
·	O
975	O
·	O
170	O
·	O
975	O
·	O
360	O
·	O
975	O
·	O
280	O
·	O
93HDL	O
-	O
cholesterol	O
(	O
mg	O
/	O
dl	O
)	O
0	O
·	O
01	O
PO	O
meal49	O
·	O
614	O
·	O
551	O
·	O
6	O
*	O
15	O
·	O
349	O
·	O
3	O
†	O
15	O
·	O
349	O
·	O
9	O
†	O
15	O
·	O
3	O
PO	O
+	O
MFGM	O
meal50	O
·	O
214	O
·	O
050	O
·	O
614	O
·	O
550	O
·	O
414	O
·	O
549	O
·	O
714	O
·	O
4HDL	O
-	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O
0	O
·	O
01	O
PO	O
meal1	O
·	O
280	O
·	O
371	O
·	O
34	O
*	O
0	O
·	O
401	O
·	O
28	O
†	O
0	O
·	O
401	O
·	O
29	O
†	O
0	O
·	O
40	O
PO	O
+	O
MFGM	O
meal1	O
·	O
300	O
·	O
361	O
·	O
310	O
·	O
381	O
·	O
300	O
·	O
371	O
·	O
290	O
·	O
37TAG	O
(	O
mg	O
/	O
dl	O
)<	O
0	O
·	O
0005	O
PO	O
meal126	O
·	O
656	O
·	O
5182	O
·	O
9	O
*	O
77	O
·	O
9223	O
·	O
9	O
*†	O
114	O
·	O
4209	O
·	O
6	O
*‡	O
82	O
·	O
9	O
PO	O
+	O
MFGM	O
meal130	O
·	O
170	O
·	O
6174	O
·	O
958	O
·	O
2265	O
·	O
1119	O
·	O
8210	O
·	O
4111	O
·	O
8TAG	O
(	O
mmol	O
/	O
l	O
)<	O
0	O
·	O
0005	O
PO	O
meal1	O
·	O
430	O
·	O
642	O
·	O
07	O
*	O
0	O
·	O
882	O
·	O
53	O
*†	O
1	O
·	O
292	O
·	O
37	O
*‡	O
0	O
·	O
94	O
PO	O
+	O
MFGM	O
meal1	O
·	O
470	O
·	O
801	O
·	O
980	O
·	O
663	O
·	O
001	O
·	O
352	O
·	O
381	O
·	O
26Non	O
-	O
HDL	O
-	O
cholesterol	O
(	O
mg	O
/	O
dl	O
)	O
0	O
·	O
04	O
PO	O
meal145	O
·	O
435	O
·	O
3152	O
·	O
6	O
*	O
36	O
·	O
5152	O
·	O
2	O
*	O
36	O
·	O
3154	O
·	O
0	O
*	O
37	O
·	O
2	O
PO	O
+	O
MFGM	O
meal148	O
·	O
534	O
·	O
9180	O
·	O
5166	O
·	O
6157	O
·	O
034	O
·	O
5154	O
·	O
033	O
·	O
8Non	O
-	O
HDL	O
-	O
cholesterol	O
(	O
mmol	O
/	O
l	O
)	O
0	O
·	O
04	O
PO	O
meal3	O
·	O
770	O
·	O
913	O
·	O
95	O
*	O
0	O
·	O
953	O
·	O
94	O
*	O
0	O
·	O
943	O
·	O
99	O
*	O
0	O
·	O
96	O
PO	O
+	O
MFGM	O
meal3	O
·	O
850	O
·	O
904	O
·	O
674	O
·	O
324	O
·	O
070	O
·	O
893	O
·	O
990	O
·	O
88Insulin	O
(	O
μIU	O
/	O
ml	O
)<	O
0	O
·	O
0005	O
PO	O
meal14	O
·	O
06	O
·	O
181	O
·	O
7	O
*	O
69	O
·	O
334	O
·	O
4	O
*†	O
28	O
·	O
6Not	O
measured	O
PO	O
+	O
MFGM	O
meal16	O
·	O
410	O
·	O
654	O
·	O
846	O
·	O
139	O
·	O
625	O
·	O
9Not	O
measuredInsulin	O
(	O
pmol	O
/	O
l	O
)<	O
0	O
·	O
0005	O
PO	O
meal100	O
·	O
744	O
·	O
1586	O
·	O
4	O
*	O
497	O
·	O
4246	O
·	O
5	O
*†	O
205	O
·	O
5Not	O
measured	O
PO	O
+	O
MFGM	O
meal117	O
·	O
575	O
·	O
9392	O
·	O
9330	O
·	O
4283	O
·	O
8186	O
·	O
0Not	O
measuredPO	O
,	O
palm	O
oil	O
;	O
PO	O
+	O
MFGM	O
,	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
.*	O
Significantly	O
different	O
from	O
0	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).†	O
Significantly	O
different	O
from	O
1	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).‡	O
Significantly	O
different	O
from	O
3	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).	O

The	O
total	O
concentration	O
of	O
each	O
analyte	O
over	O
the	O
6	O
h	O
postprandial	O
time	O
was	O
calculated	O
as	O
the	O
iAUC	O
and	O
compared	O
between	O
test	O
meals	O
.	O

The	O
addition	O
of	O
MFGM	O
to	O
the	O
test	O
meal	O
resulted	O
in	O
significantly	O
lower	O
concentrations	O
of	O
total	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
02	O
with	O
all	O
subjects	O
included	O
,	O
P	O
=	O
0	O
·	O
04	O
with	O
two	O
outliers	O
removed	O
),	O
LDL	O
-	O
cholesterol	O
(	O
P	O
=	O
0	O
·	O
046	O
)	O
and	O
a	O
significantly	O
higher	O
concentration	O
of	O
TAG	O
(	O
P	O
=	O
0	O
·	O
025	O
)	O
when	O
compared	O
with	O
the	O
PO	O
meal	O
alone	O
(	O
Supplementary	O
Fig	O
.	O

S1	O
).	O

When	O
total	O
insulin	B-GP
concentration	O
was	O
compared	O
over	O
the	O
6	O
h	O
postprandial	O
period	O
(	O
i	O
.	O
e	O
.	O
the	O
iAUC	O
of	O
insulin	B-GP
from	O
0	O
to	O
6	O
h	O
)	O
the	O
addition	O
of	O
MFGM	O
resulted	O
in	O
a	O
significantly	O
lower	O
exposure	O
to	O
insulin	B-GP
(	O
P	O
=	O
0	O
·	O
005	O
)	O
(	O
Fig	O
.	O
2	O
).	O

Neither	O
insulin	B-GP
nor	O
glucose	O
concentrations	O
at	O
baseline	O
differed	O
between	O
the	O
two	O
test	O
meals	O
.	O

There	O
were	O
no	O
effects	O
of	O
treatment	O
on	O
insulin	B-GP
and	O
glucose	O
concentrations	O
in	O
the	O
postprandial	O
period	O
;	O
however	O
,	O
there	O
was	O
a	O
rapid	O
increase	O
in	O
insulin	B-GP
concentration	O
from	O
0	O
to	O
1	O
h	O
(	O
P	O
<	O
0	O
·	O
0005	O
)	O
that	O
was	O
complemented	O
by	O
a	O
decrease	O
in	O
glucose	O
(	O
P	O
<	O
0	O
·	O
0005	O
).	O

From	O
1	O
to	O
3	O
h	O
there	O
was	O
an	O
increase	O
back	O
to	O
baseline	O
levels	O
for	O
glucose	O
(	O
P	O
=	O
0	O
·	O
003	O
)	O
and	O
a	O
corresponding	O
decrease	O
in	O
insulin	B-GP
concentrations	O
(	O
P	O
<	O
0	O
·	O
0005	O
)	O
although	O
still	O
greater	O
than	O
the	O
0	O
h	O
value	O
(	O
P	O
<	O
0	O
·	O
0005	O
).	O

The	O
increase	O
in	O
insulin	B-GP
concentration	O
was	O
dampened	O
from	O
0	O
to	O
1	O
h	O
by	O
more	O
than	O
50	O
%	O
when	O
MFGM	O
was	O
added	O
to	O
the	O
test	O
meal	O
,	O
resulting	O
in	O
a	O
482	O
%	O
increase	O
v	O
.	O
a	O
234	O
%	O
increase	O
for	O
PO	O
v	O
.	O

PO	O
+	O
MFGM	O
,	O
respectively	O
(	O
time	O
×	O
treatment	O
effect	O
,	O
P	O
<	O
0	O
·	O
0005	O
).	O
Fig	O
.	O
2	O
.	O
Postprandial	O
serum	O
insulin	B-GP
concentrations	O
.	O

Serum	O
insulin	B-GP
concentrations	O
over	O
the	O
6	O
h	O
postprandial	O
period	O
after	O
a	O
high	O
-	O
fat	O
mixed	O
meal	O
containing	O
palm	O
oil	O
(	O
PO	O
)	O
v	O
.	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
(	O
PO	O
+	O
MFGM	O
).	O

Data	O
are	O
incremental	O
AUC	O
(	O
iAUC	O
).	O

Values	O
are	O
means	O
,	O
with	O
standard	O
deviations	O
represented	O
by	O
vertical	O
bars	O
.	O
*	O
The	O
addition	O
of	O
MFGM	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
insulin	B-GP
concentration	O
(	O
P	O
=	O
0	O
·	O
005	O
).	O

To	O
examine	O
if	O
there	O
was	O
a	O
difference	O
between	O
participants	O
who	O
had	O
high	O
v	O
.	O
low	O
baseline	O
CRP	B-GP
concentrations	O
,	O
additional	O
secondary	O
analyses	O
were	O
conducted	O
.	O

Participants	O
with	O
baseline	O
CRP	B-GP
concentration	O
≥	O
3	O
mg	O
/	O
l	O
(	O
coded	O
as	O
‘	O
high	O
’)	O
had	O
significantly	O
higher	O
insulin	B-GP
concentrations	O
at	O
1	O
h	O
after	O
consuming	O
the	O
PO	O
meal	O
(	O
P	O
=	O
0	O
·	O
03	O
).	O

The	O
addition	O
of	O
MFGM	O
to	O
the	O
meal	O
suppressed	O
the	O
insulin	B-GP
response	O
in	O
the	O
high	O
CRP	B-GP
group	O
,	O
thus	O
removing	O
any	O
significant	O
difference	O
between	O
the	O
high	O
and	O
low	O
CRP	B-GP
groups	O
(	O
Fig	O
.	O
3	O
).	O
Fig	O
.	O
3	O
.	O
Insulin	B-GP
concentrations	O
in	O
high	O
(––)	O
v	O
.	O
low	O
(––)	O
baseline	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
(	O
CRP	B-GP
)	O
groups	O
.	O

(	O
a	O
)	O
There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
high	O
and	O
low	O
baseline	O
CRP	B-GP
groups	O
at	O
the	O
1	O
h	O
time	O
point	O
(	O
P	O
=	O
0	O
·	O
03	O
)	O
after	O
consuming	O
the	O
palm	O
oil	O
meal	O
.	O

(	O
b	O
)	O
When	O
the	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
meal	O
was	O
consumed	O
there	O
was	O
no	O
difference	O
between	O
the	O
high	O
and	O
low	O
baseline	O
CRP	B-GP
groups	O
for	O
insulin	B-GP
.	O

Values	O
are	O
means	O
,	O
with	O
standard	O
deviations	O
represented	O
by	O
vertical	O
bars	O
.	O

To	O
convert	O
insulin	B-GP
to	O
pmol	O
/	O
l	O
,	O
multiply	O
by	O
6	O
·	O
945	O
.	O

Inflammatory	O
markers	O

The	O
two	O
cytokines	B-GP
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
4	I-GP
fell	O
below	O
the	O
detection	O
limit	O
for	O
70	O
and	O
95	O
%	O
of	O
samples	O
,	O
respectively	O
.	O

Consequently	O
,	O
these	O
markers	O
were	O
not	O
included	O
in	O
the	O
statistical	O
analyses	O
reported	O
here	O
.	O

Similar	O
results	O
for	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
4	I-GP
have	O
been	O
observed	O
in	O
previous	O
studies	O
(	O
41	O
,	O
42	O
).	O

Baseline	O
concentrations	O
of	O
all	O
markers	O
related	O
to	O
inflammation	O
were	O
comparable	O
between	O
the	O
two	O
treatments	O
.	O

When	O
analysed	O
as	O
iAUC	O
,	O
IL	B-GP
-	I-GP
10	I-GP
was	O
significantly	O
higher	O
(	O
P	O
=	O
0	O
·	O
013	O
)	O
and	O
sICAM	B-GP
was	O
significantly	O
lower	O
in	O
response	O
to	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
(	O
P	O
=	O
0	O
·	O
005	O
for	O
all	O
)	O
(	O
Fig	O
.	O
4	O
).	O

An	O
interaction	O
effect	O
between	O
time	O
and	O
treatment	O
was	O
observed	O
for	O
IL	B-GP
-	I-GP
10	I-GP
(	O
P	O
=	O
0	O
·	O
03	O
),	O
IL	B-GP
-	I-GP
8	I-GP
(	O
P	O
=	O
0	O
·	O
04	O
)	O
and	O
sICAM	B-GP
(	O
P	O
=	O
0	O
·	O
02	O
)	O
(	O
Table	O
4	O
).	O

Over	O
time	O
IL	B-GP
-	I-GP
10	I-GP
gradually	O
,	O
but	O
not	O
significantly	O
,	O
declined	O
on	O
the	O
PO	O
treatment	O
whereas	O
on	O
the	O
PO	O
+	O
MFGM	O
treatment	O
IL	B-GP
-	I-GP
10	I-GP
increased	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
IL	B-GP
-	I-GP
8	I-GP
from	O
0	O
–	O
3	O
h	O
and	O
1	O
–	O
3	O
h	O
and	O
a	O
significant	O
increase	O
in	O
concentration	O
from	O
the	O
3	O
–	O
6	O
h	O
time	O
points	O
(	O
P	O
<	O
0	O
·	O
05	O
for	O
all	O
)	O
following	O
the	O
PO	O
meal	O
,	O
but	O
IL	B-GP
-	I-GP
8	I-GP
was	O
unchanged	O
after	O
the	O
PO	O
+	O
MFGM	O
meal	O
.	O

Concentrations	O
for	O
sICAM	B-GP
significantly	O
increased	O
from	O
0	O
–	O
1	O
h	O
,	O
0	O
–	O
6	O
h	O
,	O
and	O
3	O
–	O
6	O
h	O
and	O
significantly	O
decreased	O
between	O
the	O
1	O
–	O
3	O
h	O
time	O
points	O
(	O
P	O
<	O
0	O
·	O
05	O
for	O
all	O
)	O
after	O
consumption	O
of	O
the	O
PO	O
meal	O
and	O
,	O
like	O
IL	B-GP
-	I-GP
8	I-GP
,	O
was	O
unchanged	O
after	O
the	O
PO	O
+	O
MFGM	O
challenge	O
.	O

There	O
was	O
no	O
treatment	O
effect	O
observed	O
for	O
any	O
of	O
the	O
other	O
inflammatory	O
markers	O
,	O
but	O
a	O
significant	O
change	O
over	O
time	O
was	O
observed	O
for	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
TNFα	B-GP
,	O
CRP	B-GP
,	O
serum	B-GP
amyloid	I-GP
A	I-GP
,	O
sICAM	B-GP
,	O
soluble	O
vascular	B-GP
adhesion	I-GP
molecule	I-GP
and	O
cortisol	O
(	O
P	O
<	O
0	O
·	O
05	O
for	O
all	O
)	O
(	O
Table	O
4	O
).	O

There	O
was	O
no	O
time	O
or	O
treatment	O
effect	O
for	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
.	O
Fig	O
.	O
4	O
.	O
Postprandial	O
serum	O
concentrations	O
of	O
IL	B-GP
-	I-GP
10	I-GP
(	O
a	O
)	O
and	O
soluble	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
(	O
sICAM	B-GP
)	O
(	O
b	O
).	O

Serum	O
IL	B-GP
-	I-GP
10	I-GP
and	O
sICAM	B-GP
concentrations	O
over	O
the	O
6	O
h	O
postprandial	O
period	O
after	O
a	O
high	O
-	O
fat	O
mixed	O
meal	O
containing	O
palm	O
oil	O
(	O
PO	O
)	O
v	O
.	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
(	O
PO	O
+	O
MFGM	O
).	O

Data	O
are	O
incremental	O
AUC	O
(	O
iAUC	O
).	O

Values	O
are	O
means	O
,	O
with	O
standard	O
deviations	O
represented	O
by	O
vertical	O
bars	O
.	O

(	O
a	O
)	O
*	O
The	O
addition	O
of	O
MFGM	O
resulted	O
in	O
a	O
significant	O
increase	O
of	O
anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
10	I-GP
(	O
P	O
=	O
0	O
·	O
011	O
).	O

(	O
b	O
)	O
*	O
The	O
addition	O
of	O
MFGM	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
sICAM	B-GP
concentration	O
(	O
P	O
=	O
0	O
·	O
013	O
).	O

The	O
sICAM	B-GP
graph	O
and	O
data	O
exclude	O
two	O
subjects	O
who	O
were	O
deemed	O
outliers	O
with	O
values	O
more	O
than	O
three	O
box	O
lengths	O
away	O
from	O
the	O
75th	O
or	O
25th	O
percentile	O
.	O
Table	O
4	O
.	O
Concentrations	O
of	O
measured	O
inflammatory	O
markers	O
at	O
each	O
time	O
point	O
(	O
Mean	O
values	O
and	O
standard	O
deviations	O
)	O
Time	O
point0	O
h1	O
h3	O
h6	O
hMean	O
sd	O
Mean	O
sd	O
Mean	O
sd	O
Mean	O
sd	O
Time	O
×	O
treatment	O
:	O
PIL	B-GP
-	I-GP
10	I-GP
(	O
pg	O
/	O
ml	O
)	O
PO	O
meal0	O
·	O
561	O
·	O
350	O
·	O
541	O
·	O
340	O
·	O
541	O
·	O
200	O
·	O
511	O
·	O
300	O
·	O
03	O
PO	O
+	O
MFGM	O
meal0	O
·	O
491	O
·	O
150	O
·	O
521	O
·	O
160	O
·	O
521	O
·	O
090	O
·	O
571	O
·	O
10IL	B-GP
-	I-GP
6	I-GP
(	O
pg	O
/	O
ml	O
)	O
PO	O
meal0	O
·	O
741	O
·	O
070	O
·	O
59	O
*	O
0	O
·	O
860	O
·	O
61	O
*	O
1	O
·	O
080	O
·	O
76	O
†‡	O
1	O
·	O
140	O
·	O
48	O
PO	O
+	O
MFGM	O
meal0	O
·	O
721	O
·	O
350	O
·	O
591	O
·	O
230	O
·	O
540	O
·	O
950	O
·	O
761	O
·	O
36IL	B-GP
-	I-GP
8	I-GP
(	O
pg	O
/	O
ml	O
)	O
PO11	O
·	O
243	O
·	O
0610	O
·	O
51	O
*	O
3	O
·	O
309	O
·	O
63	O
*	O
3	O
·	O
1110	O
·	O
962	O
·	O
910	O
·	O
04	O
PO	O
+	O
MFGM11	O
·	O
113	O
·	O
2811	O
·	O
323	O
·	O
2310	O
·	O
722	O
·	O
6610	O
·	O
83	O
·	O
30TNFα	B-GP
(	O
pg	O
/	O
ml	O
)	O
PO	O
meal2	O
·	O
490	O
·	O
702	O
·	O
360	O
·	O
562	O
·	O
290	O
·	O
622	O
·	O
360	O
·	O
640	O
·	O
13	O
PO	O
+	O
MFGM	O
meal2	O
·	O
340	O
·	O
662	O
·	O
360	O
·	O
642	O
·	O
270	O
·	O
612	O
·	O
220	O
·	O
66IL	B-GP
-	I-GP
18	I-GP
(	O
pg	O
/	O
ml	O
)	O
PO	O
meal145	O
·	O
4891	O
·	O
64148	O
·	O
4475	O
·	O
95162	O
·	O
38109	O
·	O
73150	O
·	O
9573	O
·	O
050	O
·	O
59	O
PO	O
+	O
MFGM	O
meal154	O
·	O
2583	O
·	O
16152	O
·	O
1973	O
·	O
41155	O
·	O
3878	O
·	O
06160	O
·	O
0372	O
·	O
09MCP	B-GP
-	I-GP
1	I-GP
(	O
pg	O
/	O
ml	O
)	O
PO	O
meal345	O
·	O
7593	O
·	O
66343	O
·	O
23104	O
·	O
24336	O
·	O
7294	O
·	O
82330	O
·	O
8182	O
·	O
090	O
·	O
26	O
PO	O
+	O
MFGM	O
meal352	O
·	O
1684	O
·	O
36358	O
·	O
6190	O
·	O
41320	O
·	O
46102	O
·	O
57335	O
·	O
0597	O
·	O
92CRP	O
(	O
mg	O
/	O
l	O
)	O
PO	O
meal4	O
·	O
424	O
·	O
694	O
·	O
394	O
·	O
234	O
·	O
424	O
·	O
434	O
·	O
64	O
†	O
4	O
·	O
640	O
·	O
8	O
PO	O
+	O
MFGM	O
meal4	O
·	O
374	O
·	O
295	O
·	O
165	O
·	O
565	O
·	O
115	O
·	O
545	O
·	O
205	O
·	O
38SAA	B-GP
(	O
mg	O
/	O
l	O
)	O
PO	O
meal3	O
·	O
933	O
·	O
484	O
·	O
043	O
·	O
583	O
·	O
81	O
†	O
3	O
·	O
224	O
·	O
12	O
‡	O
3	O
·	O
710	O
·	O
91	O
PO	O
+	O
MFGM	O
meal11	O
·	O
8530	O
·	O
7912	O
·	O
7632	O
·	O
7612	O
·	O
2031	O
·	O
6812	O
·	O
8233	O
·	O
37sICAM	B-GP
-	I-GP
1	I-GP
(	O
mg	O
/	O
l	O
)	O
PO	O
meal0	O
·	O
970	O
·	O
501	O
·	O
06	O
*	O
0	O
·	O
531	O
·	O
00	O
†	O
0	O
·	O
501	O
·	O
04	O
*‡	O
0	O
·	O
530	O
·	O
02	O
PO	O
+	O
MFGM	O
meal0	O
·	O
960	O
·	O
510	O
·	O
970	O
·	O
500	O
·	O
950	O
·	O
500	O
·	O
970	O
·	O
51sVCAM	B-GP
-	I-GP
1	I-GP
(	O
mg	O
/	O
l	O
)	O
PO	O
meal1	O
·	O
550	O
·	O
851	O
·	O
65	O
*	O
0	O
·	O
861	O
·	O
58	O
†	O
0	O
·	O
861	O
·	O
62	O
‡	O
0	O
·	O
860	O
·	O
13	O
PO	O
+	O
MFGM	O
meal1	O
·	O
490	O
·	O
831	O
·	O
510	O
·	O
841	O
·	O
460	O
·	O
821	O
·	O
520	O
·	O
85Cortisol	O
(	O
μg	O
/	O
l	O
)	O
PO	O
meal1139751820859967108659595703305	O
*†	O
457081653937	O
*†‡	O
5773520	O
·	O
76	O
PO	O
+	O
MFGM	O
meal1083979698219933085619060780686476281613297366507PO	O
,	O
palm	O
oil	O
;	O
PO	O
+	O
MFGM	O
,	O
palm	O
oil	O
+	O
milk	O
fat	O
globule	O
membrane	O
;	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
;	O
CRP	B-GP
,	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
;	O
SAA	B-GP
,	O
serum	B-GP
amyloid	I-GP
A	I-GP
;	O
sICAM	B-GP
,	O
soluble	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
;	O
sVCAM	B-GP
,	O
soluble	O
vascular	B-GP
adhesion	I-GP
molecule	I-GP
.*	O
Significantly	O
different	O
from	O
0	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).†	O
Significantly	O
different	O
from	O
1	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).‡	O
Significantly	O
different	O
from	O
3	O
h	O
when	O
both	O
treatments	O
analysed	O
together	O
(	O
P	O
<	O
0	O
·	O
05	O
).	O

Secondary	O
analysis	O
using	O
baseline	O
CRP	B-GP
as	O
a	O
covariate	O
revealed	O
a	O
statistically	O
significant	O
difference	O
for	O
IL	B-GP
-	I-GP
6	I-GP
at	O
each	O
time	O
point	O
(	O
P	O
<	O
0	O
·	O
05	O
for	O
each	O
time	O
point	O
)	O
between	O
participants	O
with	O
high	O
v	O
.	O
low	O
baseline	O
CRP	B-GP
concentrations	O
after	O
consuming	O
the	O
PO	O
test	O
meal	O
.	O

After	O
consuming	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
,	O
this	O
difference	O
was	O
no	O
longer	O
significant	O
,	O
suggesting	O
that	O
MFGM	O
may	O
attenuate	O
the	O
postprandial	O
inflammatory	O
response	O
in	O
individuals	O
with	O
high	O
CRP	B-GP
levels	O
.	O

Cortisol	O

Analysis	O
of	O
serum	O
cortisol	O
revealed	O
no	O
time	O
×	O
treatment	O
interaction	O
effect	O
or	O
a	O
treatment	O
effect	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
cortisol	O
concentration	O
for	O
all	O
time	O
points	O
(	O
P	O
<	O
0	O
·	O
05	O
for	O
all	O
time	O
points	O
)	O
over	O
the	O
course	O
of	O
each	O
test	O
day	O
.	O

Decreases	O
throughout	O
the	O
day	O
,	O
from	O
baseline	O
to	O
1	O
h	O
,	O
1	O
–	O
3	O
h	O
,	O
and	O
3	O
–	O
6	O
h	O
were	O
as	O
follows	O
:	O
15	O
,	O
33	O
and	O
43	O
%,	O
respectively	O
.	O

This	O
observed	O
decrease	O
throughout	O
the	O
day	O
is	O
consistent	O
with	O
diurnal	O
patterns	O
of	O
cortisol	O
.	O

Discussion	O

This	O
study	O
was	O
designed	O
to	O
determine	O
if	O
the	O
addition	O
of	O
MFGM	O
to	O
a	O
high	O
-	O
fat	O
meal	O
containing	O
plant	O
-	O
based	O
saturated	O
fat	O
influences	O
postprandial	O
inflammation	O
in	O
overweight	O
and	O
obese	O
individuals	O
.	O

Our	O
results	O
showed	O
that	O
adding	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
to	O
a	O
high	O
-	O
fat	O
meal	O
may	O
lower	O
CVD	B-DS
risk	O
by	O
reducing	O
postprandial	O
insulin	B-GP
,	O
total	O
cholesterol	O
and	O
LDL	O
-	O
cholesterol	O
as	O
well	O
as	O
sICAM	B-GP
concentrations	O
while	O
increasing	O
the	O
concentration	O
of	O
anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
10	I-GP
.	O

Compared	O
with	O
PO	O
,	O
consumption	O
of	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
resulted	O
in	O
a	O
significantly	O
higher	O
concentration	O
of	O
IL	B-GP
-	I-GP
10	I-GP
at	O
6	O
h	O
postprandial	O
.	O

IL	B-GP
-	I-GP
10	I-GP
is	O
an	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
which	O
has	O
been	O
recognised	O
for	O
its	O
atheroprotective	O
effects	O
(	O
43	O
).	O

Our	O
results	O
suggest	O
that	O
the	O
addition	O
of	O
MFGM	O
to	O
a	O
high	O
-	O
SFA	O
meal	O
improves	O
postprandial	O
inflammation	O
in	O
an	O
overweight	O
and	O
obese	O
population	O
already	O
in	O
a	O
chronically	O
inflamed	O
state	O
.	O

To	O
our	O
knowledge	O
we	O
are	O
the	O
first	O
to	O
examine	O
the	O
postprandial	O
effect	O
on	O
IL	B-GP
-	I-GP
10	I-GP
after	O
a	O
high	O
-	O
fat	O
dietary	O
challenge	O
with	O
and	O
without	O
MFGM	O
in	O
human	B-OG
subjects	O
.	O

Cellular	B-GP
adhesion	I-GP
molecules	I-GP
,	O
such	O
as	O
sICAM	B-GP
,	O
are	O
key	O
players	O
in	O
the	O
early	O
events	O
of	O
atherosclerosis	O
development	O
(	O
44	O
).	O

The	O
consumption	O
of	O
the	O
PO	O
+	O
MFGM	O
test	O
meal	O
resulted	O
in	O
a	O
significantly	O
lower	O
concentration	O
of	O
sICAM	B-GP
over	O
the	O
postprandial	O
period	O
when	O
compared	O
with	O
PO	O
alone	O
.	O

In	O
large	O
prospective	O
studies	O
of	O
both	O
healthy	O
individuals	O
and	O
patients	O
with	O
CVD	B-DS
,	O
concentrations	O
of	O
sICAM	B-GP
were	O
positively	O
associated	O
with	O
future	O
incidents	O
of	O
CVD	B-DS
(	O
45	O
–	O
47	O
).	O

In	O
our	O
study	O
the	O
total	O
amount	O
of	O
sICAM	B-GP
over	O
the	O
6	O
h	O
postprandial	O
period	O
in	O
response	O
to	O
PO	O
+	O
MFGM	O
was	O
significantly	O
lower	O
by	O
95	O
%	O
compared	O
with	O
PO	O
.	O

These	O
results	O
suggest	O
that	O
the	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
attenuates	O
the	O
atherogenic	O
milieu	O
triggered	O
by	O
the	O
PO	O
meal	O
.	O

It	O
is	O
possible	O
that	O
the	O
difference	O
in	O
sICAM	B-GP
between	O
the	O
PO	O
v	O
.	O

PO	O
+	O
MFGM	O
treatments	O
could	O
stem	O
from	O
the	O
difference	O
in	O
the	O
fatty	O
acid	O
composition	O
.	O

The	O
PO	O
+	O
MFGM	O
meal	O
was	O
higher	O
in	O
short	O
-	O
and	O
medium	O
-	O
chained	O
SFA	O
and	O
lower	O
in	O
18	O
:	O
2n	O
-	O
6	O
and	O
18	O
:	O
1n	O
-	O
9	O
compared	O
with	O
the	O
PO	O
meal	O
.	O

Chen	O
et	O
al	O
.(	O
48	O
)	O
showed	O
that	O
when	O
human	B-OG
retinal	O
vascular	O
endothelial	O
cells	O
were	O
treated	O
with	O
linoleic	O
acid	O
(	O
18	O
:	O
2n	O
-	O
6	O
)	O
it	O
resulted	O
in	O
increased	O
ICAM	B-GP
expression	O
.	O

The	O
MFGM	O
preparation	O
used	O
is	O
composed	O
of	O
complex	O
lipids	O
including	O
sphingolipids	O
,	O
as	O
well	O
as	O
bioactive	O
proteins	O
,	O
which	O
may	O
also	O
play	O
roles	O
in	O
the	O
observed	O
anti	O
-	O
inflammatory	O
effects	O
(	O
49	O
).	O

When	O
analysing	O
the	O
insulin	B-GP
iAUC	O
over	O
the	O
6	O
h	O
postprandial	O
period	O
,	O
the	O
total	O
insulin	B-GP
concentration	O
was	O
significantly	O
lower	O
in	O
response	O
to	O
the	O
PO	O
+	O
MFGM	O
compared	O
with	O
the	O
PO	O
test	O
meal	O
.	O

To	O
our	O
knowledge	O
there	O
have	O
not	O
been	O
any	O
prior	O
clinical	O
trials	O
examining	O
the	O
effect	O
of	O
MFGM	O
consumption	O
on	O
the	O
insulin	B-GP
response	O
in	O
human	B-OG
subjects	O
.	O

One	O
study	O
investigated	O
the	O
postprandial	O
effect	O
of	O
adding	O
a	O
dairy	O
product	O
rich	O
in	O
sphingolipids	O
,	O
a	O
lipid	O
constituent	O
of	O
MFGM	O
,	O
to	O
a	O
high	O
-	O
fat	O
breakfast	O
meal	O
and	O
found	O
no	O
significant	O
difference	O
in	O
postprandial	O
insulin	B-GP
concentrations	O
(	O
50	O
).	O

Branched	O
-	O
chain	O
amino	O
acids	O
may	O
promote	O
insulin	B-GP
secretion	O
(	O
51	O
,	O
52	O
);	O
thus	O
the	O
effect	O
of	O
MFGM	O
on	O
insulin	B-GP
may	O
be	O
related	O
to	O
its	O
amino	O
acid	O
composition	O
.	O

The	O
secondary	O
analysis	O
based	O
on	O
baseline	O
CRP	B-GP
concentrations	O
revealed	O
that	O
participants	O
who	O
were	O
in	O
an	O
inflamed	O
state	O
(	O
CRP	B-GP
≥	O
3	O
mg	O
/	O
l	O
)	O
in	O
the	O
fasted	O
condition	O
had	O
significantly	O
higher	O
insulin	B-GP
concentrations	O
after	O
consuming	O
the	O
PO	O
meal	O
compared	O
with	O
those	O
who	O
had	O
normal	O
baseline	O
CRP	B-GP
concentrations	O
.	O

However	O
,	O
the	O
addition	O
of	O
MFGM	O
to	O
the	O
high	O
-	O
fat	O
test	O
meal	O
completely	O
removed	O
this	O
difference	O
.	O

These	O
results	O
suggest	O
an	O
interaction	O
between	O
diet	O
and	O
phenotype	O
,	O
whereby	O
consumption	O
of	O
MFGM	O
by	O
chronically	O
inflamed	O
individuals	O
normalised	O
responses	O
to	O
a	O
high	O
-	O
fat	O
meal	O
to	O
closely	O
resemble	O
that	O
of	O
a	O
metabolically	O
healthy	O
profile	O
.	O

Research	O
has	O
shown	O
that	O
cortisol	O
peaks	O
in	O
the	O
morning	O
(	O
53	O
),	O
which	O
was	O
reflected	O
in	O
the	O
present	O
study	O
,	O
and	O
decreases	O
over	O
the	O
course	O
of	O
the	O
day	O
.	O

Elevated	O
levels	O
of	O
cortisol	O
inhibit	O
the	O
synthesis	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B-GP
(	O
54	O
).	O

We	O
hypothesised	O
that	O
this	O
potential	O
inhibition	O
may	O
explain	O
the	O
observed	O
initial	O
decrease	O
in	O
the	O
pro	O
-	O
inflammatory	O
cytokines	B-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
TNFα	B-GP
)	O
from	O
baseline	O
(	O
blood	O
draw	O
schedule	O
between	O
08	O
·	O
00	O
and	O
09	O
·	O
00	O
hours	O
)	O
to	O
the	O
3	O
h	O
blood	O
draw	O
(	O
scheduled	O
between	O
11	O
·	O
00	O
and	O
12	O
·	O
00	O
hours	O
).	O

However	O
,	O
none	O
of	O
the	O
correlations	O
was	O
significant	O
.	O

In	O
summary	O
,	O
the	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
reduced	O
the	O
iAUC	O
in	O
postprandial	O
insulin	B-GP
,	O
total	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
and	O
sICAM	B-GP
responses	O
over	O
the	O
6	O
h	O
postprandial	O
period	O
,	O
and	O
increased	O
the	O
production	O
of	O
the	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
IL	B-GP
-	I-GP
10	I-GP
.	O

The	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
also	O
attenuated	O
the	O
increases	O
in	O
insulin	B-GP
at	O
1	O
h	O
in	O
individuals	O
with	O
elevated	O
fasting	O
CRP	B-GP
.	O

Results	O
from	O
this	O
study	O
suggest	O
that	O
the	O
addition	O
of	O
a	O
dairy	O
fraction	O
rich	O
in	O
MFGM	O
attenuates	O
the	O
negative	O
metabolic	O
and	O
inflammatory	O
effects	O
of	O
a	O
high	O
-	O
fat	O
meal	O
rich	O
in	O
saturated	O
fat	O
,	O
specifically	O
palmitate	O
.	O

click	O
here	O
to	O
view	O
supplementary	O
material	O

